Abstract
The pharmacokinetics of high-dose busulphan was studied in 17 patients during conditioning prior to bone marrow transplantation using deuterium-labeled busulphan (d8-BU). About 50% of busulphan doses 1 and 16 was replaced with d8-BU. Patients were treated with phenytoin or diazepam as prophylactic anticonvulsant therapy. Patients who received phenytoin demonstrated significantly higher clearance (mean ±SD, 3.32±0.99 ml min−1 kg−1), a lower area under the concentration-time curve (AUC, 5,412±1,534 ng h ml−1; corrected for dose/kilogram) and a shorter elimination half-life (3.03±0.57 h) for the last dose of d8-BU (dose 16) as compared with the first dose (2.80±0.78 ml min−1 kg−1, 6,475±2,223 ng h ml−1 and 3.94±1.10 h, respectively). No difference in the above-mentioned pharmacokinetic parameters was seen in patients treated with diazepam. Moreover, a continuous decrease in the steady-state level of busulphan was observed in four of seven patients in the phenytoin-treated group, whereas in the diazepam group, such a decrease was seen in only one of eight patients. We conclude that phenytoin used as prophylactic anticonvulsant therapy alters busulphan pharmacokinetics and, most probably, its pharmacodynamics. For adequate prophylactic therapy, anticonvulsants with fewer enzyme-inductive properties than phenytoin should be used.
Similar content being viewed by others
Abbreviations
- AML:
-
acute myelocytic leukaemia
- ALL:
-
acute lymphocytic leukaemia
- MDS:
-
myelodysplastic syndrome
- ABMT:
-
autologous bone marrow transplantation
- BMT:
-
allogeneic bone marrow transplantation
References
Appelbaum FR, Dahlberg S, Thomas ED, Buckner CD, Cheever MA, Clift RA, Crowley J, Deeg HJ, Fefer A, Greenberg PD, Kadin M, Smith W, Stewart P, Sullivan K, Storb R, Weiden P (1984) Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia. Ann Intern Med 101: 581
Hobbs JR, Hugh-Jones K, Shaw PJ, Downie CJC, Williamson S (1986) Engraftment rates related to busulphan and cyclophosphamide dosages for displacement bone marrow transplants in fifty children. Bone Marrow Transplant 1: 201
Santos GW, Tutschka PJ, Brookmeyer R, Saral R, Beschorner WE, Bias WB, Braine HG, Burns WH, Elfenbein GJ, Kaizer H, Mellits D, Sensenbrenner LL, Stuart RK, Yeager AM (1983) Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 309: 1347
Hassan M, Öberg G, Ehrsson H, Ehrnebo M, Wallin I, Smedmyr B, Tötterman T, Eksborg S, Simonsson B (1989) Pharmacokinetic and metabolic studies of high-dose busulphan in adults. Eur J Clin Pharmacol 36: 525
Vassal G, Gouyette A, Hartmann O, Pico JL, Lemerle J (1989) Pharmacokinetics of high-dose busulfan in children. Cancer Chemother Pharmacol 24: 386
Grochow LB, Krivit W, Whitley CB, Blazar B (1990) Busulfan disposition in children. Blood 75: 1723
McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED (1984) Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence and predisposing factors. Hepatology 4: 116
Morgan M, Dodds A, Atkinson K, Szer J, Downs K, Biggs J (1991) The toxicity of busulphan and cyclophosphamide as the preparative regimen for bone marrow transplantation. Br J Haematol 77: 529
Martell RW, Sher C, Jacobs P, Monteagudo F (1987) High-dose busulfan and myoclonic epilepsy. Ann Intern Med 106: 173
Sureda A, Perez de Oteyza J, Larana JG, Odriozola J (1989) High-dose busulfan and seizures. Ann Intern Med 111: 543
Marcus RE, Goldman JM (1984) Convulsions due to high-dose busulphan. Lancet II: 1463
De La Camara R, Tomas JF, Figuera A, Berberana M, Fernandez-Ranada JM (1991) High-dose busulfan and seizures. Bone Marrow Transplant 7: 363
Vassal G, Deroussent A, Hartmann O, Challine D, Benhamou E, Valteau-Couanet D, Brugieres L, Kalifa C, Gouyette A, Lemerle J (1990) Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res 50: 6203
Hassan M, Öberg G, Ericson K, Ehrsson H, Eriksson L, Ingvar M, Stone-Elander S, Thorell J-O, Smedmyr B, Warne N, Widen L (1992) In vivo distribution of [11C]-busulfan in Cynomolgus monkey and in the brain of a human patient. Cancer Chemother Pharmacol 30: 81
Hassan M, Ehrsson H, Smedmyr B, Tötterman T, Wallin I, Öberg G, Simonsson B (1989) Cerebrospinal fluid and plasma concentrations of busulfan during high-dose therapy. Bone Marrow Transplant 4: 113
Keith DA, Gundberg CM, Needleman H (1981) Microsomal enzyme induction and gingival enlargement in subjects taking phenytoin. Arch Oral Biol 26: 1095
Wolff FA de, Peters ACB, Kempen GMJ van (1982) Serum concentrations and enzyme induction in epileptic children treated with phenytoin and valproate. Neuropediatrics 13: 10
Sano J, Kawada H, Yamaguchi N, Kawakita M, Kobayashi K (1981) Effects of phenytoin on serum γ-glutamyl transpeptidase activity. Epilepsia 22: 331
Fitzsimmons WE, Ghalie R, Kaizer H (1990) Anticonvulsants and busulfan. Ann Intern Med 112: 552
Fitzsimmons WE, Ghalie R, Kaizer H (1990) The effect of hepatic enzyme inducers on busulfan neurotoxicity and myelotoxicity. Cancer Chemother Pharmacol 27: 226
Hassan M, Öberg G, Bekassy AN, Aschan J, Ehrsson H, Ljungman P, Lönnerholm G, Smedmyr B, Taube A, Wallin I, Simonsson B (1991) Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology. Cancer Chemother Pharmacol 28: 130
Hassan M, Ehrsson H (1987) Metabolism of14C-busulfan in isolated perfused rat liver. Eur J Drug Metab Pharmacokinet 12: 71
Hassan M, Ehrsson H (1987) Urinary metabolites of busulfan in the rat. Drug Metab Dispos 15: 399
Vassal G, Challine D, Koscielny S, Deroussent A, Boland I, Valteau-Counnet D, Lemerle J, Lévi F, Gouyette A (1993) Chronopharmacology of high-dose busulfan in children. Cancer Res 53: 1534
Hassan M, Ehrsson H (1983) Gas chromatographic determination of busulfan in plasma with electron-capture detection. J Chromatogr 277: 374
Ehrsson H, Hassan M (1983) Determination of busulfan in plasma by GC-MS with selected-ion monitoring. J Pharm Sci 72: 1203
Santos GW (1989) Busulfan and cyclophosphamide for marrow transplantation. Bone Marrow Transplant 4 [Suppl 1]: 236
Grigg AP, Shepherd JD, Phillips GL (1989) Busulphan and phenytoin. Ann Intern Med 111: 1049
Hassan M, Ehrsson H, Wallin I, Eksborg S (1988) Pharmacokinetic and metabolic studies of busulfan in rat plasma and brain. Eur J Drug Metab Pharmacokinet 13: 301
Scott AK, Jeffers TA, Petrie JC, Gilbert JC (1979) Serum bilirubin and hepatic enzyme induction. BMJ 2: 310
Braide SA, Davies TJ (1987) Factors that affect the induction of gamma glutamyltransferase in epileptic patients receiving anti-convulsant drugs. Ann Clin Biochem 24: 391
Jones DH, Bleehen NM, Workman P, Smith NC (1983) The role of microsomal enzyme inducers in the reduction of misonidazole neurotoxicity. Br J Radiol 56: 865
Frey BM, Frey F (1984) Phenytoin modulates the pharmacokinetics of prednisolone and the pharmacodynamics of prednisolone as assessed by the inhibition of the mixed lymphocyte reaction in humans. Eur J Clin Invest 14: 1
Perucca E, Richens A (1979) Paracetamol disposition in normal subjects and in patients treated with antiepileptic drugs. Br J Clin Pharmacol 7: 201
Woodcock BG, Kirsten R, Nelson K, Rietbrock S, Hopf R, Kaltenbach M (1989) A reduction in verapamil concentrations with phenytoin. N Engl J Med 325: 1179
Bollini P, Riva R, Albani F, Ida N, Cacciari L, Bollini C, Baruzzi A (1983) Decreased phenytoin level during antineoplastic therapy: a case report. Epilepsia 24: 75
Fincham RW, Schottelius DD (1979) Decreased phenytoin levels in antineoplastic therapy. Ther Drug Monit 1: 227
Sylvester RK, Lewis FB, Caldwell KC, Lobell M, Perri R, Sawchuk RA (1984) Impaired phenytoin bioavailability secondary to cisplatinum, vinblastine, and bleomycin. Ther Drug Monit 6: 302
Neef C, De Voogd-van der Straaten I (1988) An interaction between cytostatic and anticonvulsant drugs. Clin Pharmacol Ther 43: 372
Author information
Authors and Affiliations
Additional information
This work was supported by a grant from the Swedish Cancer Society (2805-B90-01X)
Rights and permissions
About this article
Cite this article
Hassan, M., Öberg, G., Björkholm, M. et al. Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. Cancer Chemother. Pharmacol. 33, 181–186 (1993). https://doi.org/10.1007/BF00686213
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00686213